Healthcare Industry News: Presidio Pharmaceuticals
News Release - June 21, 2007
Presidio Pharmaceuticals Announces Key Executive Management Additions
Marcus Conant, M.D. - Appointed to Chief Medical OfficerAntoun Nabhan, J.D. - Appointed to Chief Financial Officer
SAN FRANCISCO--(HSMN NewsFeed)--Presidio Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing small molecule compounds for the treatment of HIV-1, HCV and other chronic viral infections, announces today that Marcus Conant, MD has joined the company as its Chief Medical Officer, and Antoun Nabhan, JD has joined as Chief Financial Officer.
Dr. Conant is a pioneer in the identification and treatment of HIV/AIDS patients in the US. He was one of the earliest physicians to recognize diseases associated with HIV-1 in the U.S. In 1981, he identified the first cases of Kaposi's sarcoma in San Francisco and started the Kaposi's Sarcoma Clinic at the University of California, San Francisco. Dr. Conant created The Conant Medical Group HIV/AIDS Clinic, which was the largest private AIDS clinic in San Francisco, and ultimately one of the largest in the world. He was a contributor in over 25 clinical trials, involving today's leading HIV medications from Merck, Pfizer, Roche, GlaxoSmithKline, Gilead Sciences, Abbott and Tibotec.
Mr. Nabhan joins Presidio from Sagamore Bioventures, where he was a Principal. Prior to joining Sagamore he was Founder and VP of Business Development and Finance for Incellico, Inc., a systems biology discovery company acquired by Genstruct, Inc. Aside from his responsibilities at Presidio, Mr. Nabhan also currently serves on the Board of Directors of Cellerant Therapeutics and the nonprofit BayBio, and is a Board Observer for Capnia, Inc, and will retain a role in managing the investments with which he was involved while a Principal at Sagamore.
"I believe that these additions to our management team will be critical to our success in building a leading specialty pharmaceutical company pioneering new treatments for chronic viral infections," said Dr. Omar K. Haffar, Presidio's President and CEO. "Marcus' involvement as clinical investigator on many of the world's leading anti-HIV agents will be invaluable as we demonstrate the medical benefits of our products. Antoun brings to Presidio a detailed understanding of the financial operations of specialty pharmaceutical companies, and his relationships with leading investors will be valuable in helping Presidio continue to achieve its corporate goals."
About Presidio Pharmaceuticals, Inc:
Presidio Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on in-licensing, developing and commercializing novel therapeutics for chronic viral infections, including but not limited to HIV-1, CMV, and HCV. Presidio Pharmaceuticals was founded in March 2006 with an initial investment from Sagamore Bioventures, a life science venture fund headquartered in San Francisco, CA, as well as from the George Rathmann Family Fund and Peninsula Overview Partners. www.presidiopharma.com
Source: Presidio Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
